• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for OPVEE issued to OPIANT PHARMACEUTICALS INC

    5/24/23 11:39:07 AM ET
    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPNT alert in real time by email
    New Drug Application (NDA): 217470
    Company: OPIANT PHARMACEUTICALS INC
    • Email

    Products on NDA 217470

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    OPVEE NALMEFENE 2.7MG SPRAY;NASAL Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 217470

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    05/22/2023 ORIG-1 Approval Type 3 - New Dosage Form PRIORITY Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217470Orig1s000.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217470Orig1s000ltr.pdf

    Labels for NDA 217470

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    05/22/2023 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217470Orig1s000.pdf
    Get the next $OPNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPNT

    DatePrice TargetRatingAnalyst
    12/9/2021$42.00Outperform
    Oppenheimer
    More analyst ratings